Elevated serum ferritin in non-alcoholic fatty liver disease is not predictive of fibrosis.
disease
fatty
ferritin
fibrosis
liver
non-alcoholic
steatohepatitis
Journal
Canadian liver journal
ISSN: 2561-4444
Titre abrégé: Can Liver J
Pays: Canada
ID NLM: 101778326
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
10
2021
received:
06
11
2021
revised:
24
10
2021
accepted:
06
11
2021
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is common with widely ranging severity. Non-invasive risk scores for risk stratification are recommended but misclassify a significant proportion of patients. In situations where non-invasive risk scores do not provide guidance, referral is typically made to a Hepatologist for transient elastography or liver biopsy. Serum ferritin is elevated in many patients with NAFLD related to dysmetabolic and inflammatory hyperferritinemia. Ferritin is widely available and part of a standard workup for chronic liver disease. To explore the association of ferritin and risk of fibrosis in NAFLD, we reviewed patients diagnosed with NAFLD at the hepatology clinic of the Vancouver General Hospital between the years of 2015 and 2018. We collected data on 317 patients retrospectively assessing for a relationship between serum ferritin and elastography score. Two hundred twenty-four patients were included in the final analysis. Median ferritin was 145 µg/L (IQR 62-311). Median liver stiffness was 5.2 kPa with 14.3% of patients having liver stiffness ≥8.7 kPa and 17.4% ≥ 8.0 kPa. ROC curve analysis using a liver stiffness ≥8.0 kPa as a cutoff for F2 fibrosis showed an AUROC of 0.54 for serum ferritin levels. At a cut-off of both 300 µg/L; and 450 µg/L median liver stiffness did not differ significantly in those with ferritin above the cutoff (ferritin ≥300 µg/L; In this cohort of 224 patients with NAFLD, serum ferritin was not predictive of significant liver fibrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is common with widely ranging severity. Non-invasive risk scores for risk stratification are recommended but misclassify a significant proportion of patients. In situations where non-invasive risk scores do not provide guidance, referral is typically made to a Hepatologist for transient elastography or liver biopsy. Serum ferritin is elevated in many patients with NAFLD related to dysmetabolic and inflammatory hyperferritinemia. Ferritin is widely available and part of a standard workup for chronic liver disease.
METHODS
METHODS
To explore the association of ferritin and risk of fibrosis in NAFLD, we reviewed patients diagnosed with NAFLD at the hepatology clinic of the Vancouver General Hospital between the years of 2015 and 2018. We collected data on 317 patients retrospectively assessing for a relationship between serum ferritin and elastography score.
RESULTS
RESULTS
Two hundred twenty-four patients were included in the final analysis. Median ferritin was 145 µg/L (IQR 62-311). Median liver stiffness was 5.2 kPa with 14.3% of patients having liver stiffness ≥8.7 kPa and 17.4% ≥ 8.0 kPa. ROC curve analysis using a liver stiffness ≥8.0 kPa as a cutoff for F2 fibrosis showed an AUROC of 0.54 for serum ferritin levels. At a cut-off of both 300 µg/L; and 450 µg/L median liver stiffness did not differ significantly in those with ferritin above the cutoff (ferritin ≥300 µg/L;
CONCLUSION
CONCLUSIONS
In this cohort of 224 patients with NAFLD, serum ferritin was not predictive of significant liver fibrosis.
Identifiants
pubmed: 35991481
doi: 10.3138/canlivj-2021-0002
pmc: PMC9236592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152-159Informations de copyright
Copyright © 2022 Canadian Association for the Study of the Liver.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Gut. 2010 Sep;59(9):1265-9
pubmed: 20801772
Blood Rev. 2009 May;23(3):95-104
pubmed: 18835072
Korean J Gastroenterol. 2006 Jun;47(6):432-9
pubmed: 16809950
J Hepatol. 2019 Aug;71(2):371-378
pubmed: 30965069
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
Semin Liver Dis. 2019 Nov;39(4):476-482
pubmed: 31330553
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
Hepatology. 2012 Jun;55(6):2005-23
pubmed: 22488764
Hepatol Res. 2018 Feb;48(3):E30-E41
pubmed: 28593739
Hepatology. 2019 Nov;70(5):1521-1530
pubmed: 31271665
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
Aliment Pharmacol Ther. 2019 Mar;49(6):681-701
pubmed: 30761559
Can J Gastroenterol. 2008 Jan;22(1):37-40
pubmed: 18209779
Hepatology. 2010 Feb;51(2):454-62
pubmed: 20101745
PLoS One. 2008;3(10):e3547
pubmed: 18958176